Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

P Hughes, Tim; Kaeda, Jaspal; Branford, Susan; Rudzki, Zbigniew; Hochhaus, Andreas; L Hensley, Martee; Gathmann, Insa; E Bolton, Ann; C van Hoomissen, Iris; M Goldman, John; P Radich, Jerald; Randomised Study of Interferon versus STI571 (IRIS) Study Group, International

doi:10.1056/nejmoa030513

Public

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Shared by NobleBlocks on Oct 9, 2003 • 12:00 AM UTC

Authors:

Tim P Hughes

Jaspal Kaeda

Susan Branford

Abstract

BACKGROUND: In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic r...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!